Drug Combination Details
| General Information of the Combination (ID: C23185) | |||||
|---|---|---|---|---|---|
| Name | Ceramide NP Info | + | N, N-dimethyl-D-erythro-sphingosine Drug Info | ||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Increase | Mitochondrial membrane potential loss | ||||
| In-vitro Model | LL/2 (LLC1) | CVCL_4358 | Malignant tumors | Mus musculus | ||
| Experimental
Result(s) |
The radiosensitizing activity of ceramide/DMS on LLC cells most likely reflects the dominance of pro-apoptotic signals related to the mitochondria-dependent pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Enhancement of radiosensitivity by combined ceramide and dimethylsphingosine treatment in lung cancer cells. Exp Mol Med. 2004 Oct 31;36(5):411-9. | |||
